Anzeige
Mehr »
Login
Freitag, 04.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DHX9 | ISIN: DK0061802139 | Ticker-Symbol: 4AJ0
Tradegate
04.04.25
08:01 Uhr
19,120 Euro
+0,070
+0,37 %
Branche
Pharma
Aktienmarkt
STOXX Europe 600
1-Jahres-Chart
ALK-ABELLO A/S Chart 1 Jahr
5-Tage-Chart
ALK-ABELLO A/S 5-Tage-Chart
RealtimeGeldBriefZeit
19,07019,24008:11
19,07019,24008:11

Aktuelle News zur ALK-ABELLO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoALK Abello: Grant of share-based long-term incentive instruments to members of the Board of Management and key employees1
13.03.ALK Abello: Annual General Meeting in ALK-Abelló A/S held on 13 March 20253
07.03.ALK Abello: ACARIZAX approved in Canada for treatment of young children230ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK's ACARIZAX® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX® is now indicated...
► Artikel lesen
04.03.ALK Abello: Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff3
ALK-ABELLO Aktie jetzt für 0€ handeln
27.02.ALK Abello: FDA approves ODACTRA for the treatment of house dust mite allergy in young children266ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK's ODACTRA® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA®...
► Artikel lesen
21.02.ALK Abello: Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff3
19.02.ALK-Abelló projects 9%-13% revenue growth for 2025 driven by global tablet expansion1
19.02.ALK Abello: Annual General Meeting in ALK-Abelló A/S on 13 March 20252
19.02.ALK-Abello shares rise following 4Q earnings report5
19.02.ALK-Abelló A/S reports FY results3
19.02.ALK Abello: Annual report 2024: ALK delivers 15% sales growth with profits up 65%219ALK's (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the 2024 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook and represent...
► Artikel lesen
12.02.ALK Abello: Invitation to the presentation of ALK's annual report 2024 on Wednesday, 19 February 20254
31.01.ALK-Abello stock jumps as Jefferies upgrades to 'buy' on growth prospects16
30.01.ALK Abello: ALK's house dust mite tablet (ACARIZAX) now recommended by NICE for use in the UK health system335ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX® for the treatment of persistent, moderate...
► Artikel lesen
06.01.ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S4
20.12.24ALK Abello: ALK - Financial calendar for the 2025 financial year2
18.12.24ALK Abello: Positive results advance peanut tablet to phase II development175ALK's peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses imminently....
► Artikel lesen
12.12.24ALK Abello: ACARIZAX approved in Europe for treatment of young children4
27.11.24ALK Abello: ALK's pivotal phase 3 trial in children published in reputable scientific journal1
14.11.24ALK Abello: Nine-month interim report (Q3) 2024 (unaudited)187Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet sales...
► Artikel lesen
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1